Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
The Gulf Achievement of Cholesterol Targets in Out-Patients Study (GULF ACTION): Design, Rationale, and Preliminary Results
Current Vascular Pharmacology, Volume 21, No. 4, Year 2023
Notification
URL copied to clipboard!
Description
Aim: To assess the current dyslipidemia management in the Arabian Gulf region by describ-ing the demographics, study design, and preliminary results of out-patients who achieved low-density lipoprotein cholesterol (LDL-C) goals at the time of the survey. Background: The Arabian Gulf population is at high risk for atherosclerotic cardiovascular disease at younger ages. There is no up-to-date study regarding dyslipidemia management in this region, especially given the recent guideline-recommended LDL-C targets. Objective: Up-to-date comprehensive assessment of the current dyslipidemia management in the Arabian Gulf region, particularly in view of the recent evidence of the additive beneficial effects of ezetimibe and proprotein convertase subtilisin/kexin-9 (PCSK-9) inhibitors on LDL-C levels and cardiovascular outcomes. Methods: The Gulf Achievement of Cholesterol Targets in Out-Patients (GULF ACTION) is an ongo-ing national observational longitudinal registry of 3000 patients. In this study, adults ≥18 years on lipid-lowering drugs for over three months from out-patients of five Gulf countries were enrolled between January 2020 and May 2022 with planned six-month and one-year follow-ups. Results: Of the 1015 patients enrolled, 71% were male, aged 57.9±12 years. In addition, 68% had ath-erosclerotic cardiovascular disease (ASCVD), 25% of these patients achieved the LDL-C target, and 26% of the cohort were treated using combined lipid-lowering drugs, including statins. Conclusion: The preliminary results of this cohort revealed that only one-fourth of ASCVD patients achieved LDL-C targets. Therefore, GULF ACTION shall improve our understanding of current dyslipidemia management and “guideline gaps” in the Arabian Gulf region. © 2023 Bentham Science Publishers.
Authors & Co-Authors
AlBackr, Hanan B.
Saudi Arabia, Riyadh
King Khalid University Hospital
Al-Mahmeed, Wael Abdulrahman R.
United Arab Emirates, Abu Dhabi
Cleveland Clinic Abu Dhabi
Amin, Mohammad I.
Bahrain, Awali
Mohammed Bin Khalifa Cardiac Centre
Batais, Mohammed Ali
Saudi Arabia, Riyadh
King Saud University
Almigbal, Turky Hamad
Saudi Arabia, Riyadh
King Saud University
Youssef, Ali Ahmed
Saudi Arabia, Dammam
Saud Albabtain Cardiac Center
Egypt, Ismailia
Suez Canal University
Alghamdi, Mohammad
Saudi Arabia, Riyadh
National Guard Health Affairs
Saudi Arabia, Riyadh
King Saud Bin Abdulaziz University for Health Sciences
Kinsara, Abdulhalim Jamal
Saudi Arabia, Riyadh
King Saud Bin Abdulaziz University for Health Sciences
Rajan, Rajesh
Kuwait, Safat
Al-amiri Hospital
Altaradi, Hani B.
Saudi Arabia, Riyadh
King Saud University
AlHabib, Khalid Faiz
Saudi Arabia, Riyadh
King Khalid University Hospital
Statistics
Authors: 11
Affiliations: 16
Identifiers
Doi:
10.2174/1570161121666230710145604
ISSN:
15701611
Research Areas
Noncommunicable Diseases
Study Design
Cross Sectional Study
Cohort Study
Study Approach
Quantitative
Participants Gender
Male